Literature DB >> 7028786

Estimated rate of prostacyclin secretion into the circulation of normal man.

G A FitzGerald, A R Brash, P Falardeau, J A Oates.   

Abstract

The rate of secretion of prostacyclin (PGI2) into the circulation of normal man was estimated by measurement of the 2,3-dinor-6-keto-PGF1 alpha (D) and 15-keto-13,14-dihydro-2,3-dinor-6-keto-PGF1 alpha (KDD) urinary metabolites of PGI2. Subjects received 6-h intravenous infusions of vehicle alone and PGI2 at 0.1, 0.4, and 2.0 ng/kg per min in random order. The fractional elimination of the metabolites was independent of the rate of PGI2 infusion. 6.8 +/- 0.3% of the infused PGI2 appeared as D and 4.1 +/- 0.4% as KDD. The regression of infused PGI2 upon the quantities of the two metabolites excreted in excess of control values permitted estimation of the rate of entry of endogenous PGI2 into the circulation corresponding to a given quantity of metabolite excreted. Using the quantities excreted in the 24 h from commencement of the infusions the estimated rates were 0.08 +/- 0.02 ng/kg per min from D and 0.10 +/- 0.03 from KDD. Studies with exogenous PGI2 suggest that infusion rates 2--4 ng/kg per min are required to achieve the threshold for inhibition of platelet function (ex vivo) in man. Although not precluding a role for PGI2 in local platelet-vessel wall interactions, the much lower estimates obtained in this study suggest that endogenous PGI2 is unlikely to act as a circulating antiplatelet agent in healthy man.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7028786      PMCID: PMC370922          DOI: 10.1172/jci110373

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

Review 1.  Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis.

Authors:  S Moncada; J R Vane
Journal:  Br Med Bull       Date:  1978-05       Impact factor: 4.291

2.  Antibodies which antagonise the effects of prostacyclin.

Authors:  J B Smith; M L Ogletree; A M Lefer; J C Nicolaou
Journal:  Nature       Date:  1978-07-06       Impact factor: 49.962

3.  Generation of prostacyclin by lungs in vivo and its release into the arterial circulation.

Authors:  R J Gryglewski; R Korbut; A Ocetkiewicz
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

4.  Prostacyclin is a circulating hormone.

Authors:  S Moncada; R Korbut; S Bunting; J R Vane
Journal:  Nature       Date:  1978-06-29       Impact factor: 49.962

5.  Production of 6-oxo-PGF1 alpha by human lung in vivo.

Authors:  C N Hensby; P J Barnes; C T Dollery; H Dargie
Journal:  Lancet       Date:  1979-12-01       Impact factor: 79.321

6.  Prostaglandins: their disappearance from and release into the circulation.

Authors:  S H Ferreira; J R Vane
Journal:  Nature       Date:  1967-12-02       Impact factor: 49.962

7.  A sensitive radioimmunoassay for 6-keto-prostaglandin F1alpha: preliminary observations on circulating concentrations.

Authors:  M D Mitchell
Journal:  Prostaglandins Med       Date:  1978-07

8.  In vivo method for quantitation for anti-platelet potency of drugs.

Authors:  R J Gryglewski; R Korbut; A Ocetkiewicz; J Stachura
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978-03       Impact factor: 3.000

9.  Comparison of the vasodepressor effects of prostacyclin and 6-oxo-prostaglandin F1alpha with those of prostaglandin E2 in rats and rabbits.

Authors:  J M Armstrong; N Lattimer; S Moncada; J R Vane
Journal:  Br J Pharmacol       Date:  1978-01       Impact factor: 8.739

10.  Quantitative determination of 6-Oxo-PGF1 alpha in biological fluids by gas chromatography mass spectrometry.

Authors:  M Claeys; C Van Hove; A Duchateau; A G Herman
Journal:  Biomed Mass Spectrom       Date:  1980-11
View more
  52 in total

Review 1.  The eicosanoids and their biochemical mechanisms of action.

Authors:  W L Smith
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

2.  Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man.

Authors:  D Gregov; A Jenkins; E Duncan; D Siebert; S Rodgers; B Duncan; F Bochner; J Lloyd
Journal:  Br J Clin Pharmacol       Date:  1987-10       Impact factor: 4.335

Review 3.  Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities.

Authors:  Tilo Grosser; Susanne Fries; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2006-01       Impact factor: 14.808

Review 4.  Antiplatelet drugs.

Authors:  Gustav Born; Carlo Patrono
Journal:  Br J Pharmacol       Date:  2006-01       Impact factor: 8.739

5.  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.

Authors:  P Patrignani; P Filabozzi; C Patrono
Journal:  J Clin Invest       Date:  1982-06       Impact factor: 14.808

6.  Biosynthesis of 15-deoxy-delta12,14-PGJ2 and the ligation of PPARgamma.

Authors:  L Chastine Bell-Parikh; Tomomi Ide; John A Lawson; Peter McNamara; Muredach Reilly; Garret A FitzGerald
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

7.  Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor.

Authors:  J M Ritter
Journal:  Br J Pharmacol       Date:  1984-10       Impact factor: 8.739

8.  Release of prostacyclin from the human pulmonary vascular bed in response to cholinergic stimulation.

Authors:  R Brandt; A Dembińska-Kieć; R Korbut; R J Gryglewski; J Nowak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-01       Impact factor: 3.000

Review 9.  Interactions of NSAIDs with diuretics and beta-blockers mechanisms and clinical implications.

Authors:  J Webster
Journal:  Drugs       Date:  1985-07       Impact factor: 9.546

10.  Contribution of prostaglandins to the systemic and renal vascular response to frusemide in normal man.

Authors:  I G Mackay; A L Muir; M L Watson
Journal:  Br J Clin Pharmacol       Date:  1984-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.